IL249327A0 - mic-1 fusion proteins and their uses - Google Patents

mic-1 fusion proteins and their uses

Info

Publication number
IL249327A0
IL249327A0 IL249327A IL24932716A IL249327A0 IL 249327 A0 IL249327 A0 IL 249327A0 IL 249327 A IL249327 A IL 249327A IL 24932716 A IL24932716 A IL 24932716A IL 249327 A0 IL249327 A0 IL 249327A0
Authority
IL
Israel
Prior art keywords
mic
fusion proteins
fusion
proteins
Prior art date
Application number
IL249327A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL249327A0 publication Critical patent/IL249327A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL249327A 2014-06-24 2016-12-01 mic-1 fusion proteins and their uses IL249327A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173664 2014-06-24
PCT/EP2015/063596 WO2015197446A1 (en) 2014-06-24 2015-06-17 Mic-1 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
IL249327A0 true IL249327A0 (en) 2017-02-28

Family

ID=51032955

Family Applications (1)

Application Number Title Priority Date Filing Date
IL249327A IL249327A0 (en) 2014-06-24 2016-12-01 mic-1 fusion proteins and their uses

Country Status (15)

Country Link
US (2) US9272019B2 (enExample)
EP (1) EP3160496B1 (enExample)
JP (1) JP6696915B2 (enExample)
KR (1) KR20170020383A (enExample)
CN (1) CN106459222A (enExample)
AR (1) AR100945A1 (enExample)
AU (1) AU2015279525A1 (enExample)
BR (1) BR112016029848A2 (enExample)
CA (1) CA2952293A1 (enExample)
IL (1) IL249327A0 (enExample)
MX (1) MX2016016063A (enExample)
RU (1) RU2017101436A (enExample)
TW (1) TW201613958A (enExample)
WO (1) WO2015197446A1 (enExample)
ZA (1) ZA201608214B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
TN2016000035A1 (en) 2013-07-31 2017-07-05 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MA45113A (fr) * 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
GB201615844D0 (en) * 2016-09-16 2016-11-02 Genagon Therapeutics Ab Agents for use in therapy
US20200069774A1 (en) 2016-12-06 2020-03-05 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
GB201700553D0 (en) * 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
WO2018193033A1 (en) 2017-04-20 2018-10-25 Novo Nordisk A/S Methods of purification of albumin fusion proteins
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN111954537A (zh) 2018-04-09 2020-11-17 美国安进公司 生长分化因子15融合蛋白
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
JP2021533743A (ja) 2018-08-10 2021-12-09 ノバルティス アーゲー Ｇｆｒａｌ細胞外ドメイン及び使用方法
KR20210081389A (ko) 2018-10-22 2021-07-01 얀센 파마슈티카 엔.브이. 글루카곤 유사 펩티드 1(glp1)-성장 분화 인자 15(gdf15) 융합 단백질 및 이의 용도
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
BR112022010227A2 (pt) * 2019-11-26 2022-09-13 Yuhan Corp Proteína de fusão gdf15 de ação prolongada e composição farmacêutica compreendendo a mesma
JP7796645B2 (ja) * 2019-12-09 2026-01-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
AU2020400805B2 (en) * 2019-12-11 2024-03-28 Lg Chem, Ltd. Fusion polypeptide comprising GDF15 and polypeptide region capable of O-glycosylation
CN115379850A (zh) * 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
KR102195740B1 (ko) * 2020-03-25 2020-12-28 서울대학교산학협력단 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
WO2021194257A1 (ko) * 2020-03-25 2021-09-30 (주) 업테라 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
WO2022089435A1 (en) * 2020-10-27 2022-05-05 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof
CN112694520B (zh) * 2020-12-02 2023-01-17 图凌(杭州)生物医药有限公司 一种人工多肽hm、其抗体及在病理检测中的应用
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
EP4476212A1 (en) 2022-02-10 2024-12-18 Novartis AG 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
PT2441466E (pt) 2004-04-13 2014-09-09 St Vincents Hosp Sydney Agente de inibição de mic-1
DK1751184T3 (da) * 2004-05-13 2009-11-23 Lilly Co Eli FGF-21 fusionsproteiner
WO2006010891A2 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US9714276B2 (en) 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
JP6254146B2 (ja) * 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
TN2016000035A1 (en) 2013-07-31 2017-07-05 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs

Also Published As

Publication number Publication date
US9272019B2 (en) 2016-03-01
KR20170020383A (ko) 2017-02-22
EP3160496B1 (en) 2021-03-03
EP3160496A1 (en) 2017-05-03
CA2952293A1 (en) 2015-12-30
MX2016016063A (es) 2017-03-10
US9956264B2 (en) 2018-05-01
AU2015279525A1 (en) 2016-12-15
US20160015784A1 (en) 2016-01-21
JP2017528419A (ja) 2017-09-28
CN106459222A (zh) 2017-02-22
WO2015197446A1 (en) 2015-12-30
JP6696915B2 (ja) 2020-05-20
RU2017101436A (ru) 2018-07-24
BR112016029848A2 (pt) 2017-10-24
RU2017101436A3 (enExample) 2019-02-13
ZA201608214B (en) 2018-11-28
AR100945A1 (es) 2016-11-09
US20160129083A1 (en) 2016-05-12
TW201613958A (en) 2016-04-16

Similar Documents

Publication Publication Date Title
IL249327A0 (en) mic-1 fusion proteins and their uses
ZA201603262B (en) Interleukin-2 fusion proteins and uses thereof
IL254965B (en) fusion proteins
SG11201707182WA (en) Immunomodulatory fusion proteins and uses thereof
GB201509062D0 (en) OX40L fusion proteins and uses thereof
IL246355A0 (en) p97–ids fused proteins
IL246348B (en) p97 fusion proteins
ZA201606327B (en) Uti fusion proteins
SG11201606501PA (en) Nanobody-fluorescent protein fusion
GB2543713B (en) Polymeric proteins and uses thereof
EP3237452A4 (en) Fusion proteins and methods thereof
GB201412648D0 (en) Proteins
GB201412646D0 (en) Proteins
GB201406894D0 (en) Proteins
GB201405952D0 (en) Proteins
GB201405955D0 (en) Proteins
GB201403913D0 (en) Proteins
GB201403914D0 (en) Proteins
GB201403912D0 (en) Proteins
GB201403915D0 (en) Proteins